Compare Ascendis Pharma A/S (ASND) vs Equinix Inc (EQIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Equinix Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Equinix Inc trades at $1,055 (market cap $103.67B). The key difference: Equinix Inc is far larger — about 5.8× Ascendis Pharma A/S's market cap, and Equinix Inc pays a 1.87% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | EQIX | |
|---|---|---|
Market Cap | $17.74B | $103.67B |
Sector | Health | Real Estate |
52-Week High | $277.18 | $1.12K |
52-Week Low | $163.32 | $726.09 |
Enterprise Value | $18.11B | $123.96B |
Dividend Yield | — | 1.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Equinix (EQIX) trades at $1,051.21, up 1.58% with a bearish technical signal despite strong analyst support. The data center REIT shows solid revenue growth to $9.22B in 2025 and expanding profit margins of 15.07%, though valuation metrics remain elevated with a P/E of 72.7. Recent partnerships with Cisco and NVIDIA position EQIX to capitalize on AI infrastructure demand, while negative cash flow trends and rising debt-to-asset ratios present financial concerns.
The outlook balances AI-driven growth potential against valuation and leverage risks. With 74.5% analyst buy ratings and a $1,120 consensus price target suggesting 6.5% upside, institutional sentiment remains positive. However, investors face execution risks in capital-intensive expansion and sensitivity to interest rate changes given the REIT structure and substantial debt load.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →
